# Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors

> **NCT05089266** · PHASE1 · UNKNOWN · sponsor: **Shanghai Cell Therapy Group Co.,Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** CAR T cells

## Key facts

- **NCT ID:** NCT05089266
- **Lead sponsor:** Shanghai Cell Therapy Group Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-30
- **Primary completion:** 2024-07-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089266, "Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05089266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*